View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 3, 2021

Novartis’ Kymriah trial shows response rates in follicular lymphoma

Kymriah is the first CAR-T to receive FDA approval for r/r acute lymphoblastic leukaemia and r/r diffuse large B-cell lymphoma. 

Novartis has reported that the primary analysis of the Phase II ELARA trial of Kymriah (tisagenlecleucel) showed a complete response rate (CRR) of 66% in relapsed or refractory (r/r) follicular lymphoma (FL) patients.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

A US Food and Drug Administration-approved therapy, Kymriah is the first CAR-T to receive approval in two separate indications, r/r acute lymphoblastic leukaemia and r/r diffuse large B-cell lymphoma.

This one-time therapy is developed to boost the immune system of the patients to fight cancer.

The single-arm, multi-centre, open-label Phase II ELARA trial assessed the efficacy and safety of Kymriah in adults with r/r FL. This global trial enrolled subjects from more than 30 centres in 12 countries globally.

CRR formed the primary goal of the trial, while overall response rate (ORR), duration of response (DOR), progression-free survival (PFS), overall survival (OS) and safety were included as secondary endpoints.

According to primary analysis data, Kymriah induced responses in most subjects who received the treatment, with an ORR of 86%.

The response rates were similar across high-risk subject subgroups in the trial.

However, median DOR in all responders, PFS and OS were not met, Novartis noted. The estimated DOR in subjects with CR and PFS rates were 94% and 76%, respectively at six months.

Furthermore, no grade 3/4 cytokine release syndrome, the most common side effect linked to CAR-T therapy, was observed in the trial subjects.

Novartis Oncology Cell & Gene global head Stefan Hendriks said: “The strength of these pivotal results from the ELARA trial underscore the promising potential of Kymriah in the treatment of patients with relapsed or refractory follicular lymphoma.”

The company plans to seek regulatory approvals globally for Kymriah in r/r FL treatment.

Last month, Novartis decided to terminate the two-year Phase III MERLIN clinical trial of Beovu (brolucizumab) in wet age-related macular degeneration patients despite meeting the primary endpoint.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena